Comparative skin dose measurement in the treatment of anal canal cancer: Conventional versus conformal therapy

2004 ◽  
Vol 31 (6) ◽  
pp. 1316-1321 ◽  
Author(s):  
Slobodan Devic ◽  
Gyorgy Hegyi ◽  
Té Vuong ◽  
Thierry Muanza ◽  
Ervin B. Podgorsak
Keyword(s):  
Anal Canal ◽  
Skin Dose ◽  
Anal Canal Cancer ◽  
Dose Measurement ◽  
Conformal Therapy

scholarly journals Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Angelo Tozzi ◽  
Luca Cozzi ◽  
Cristina Iftode ◽  
Annamaria Ascolese ◽  
Maria Concetta Campisi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Volumetric Modulated Arc Therapy ◽  
Anal Canal Cancer ◽  
Conformal Therapy ◽  
Arc Therapy

118 Conformal therapy as a mean to improve treatment therapeutic index for patients with anal canal cancer

2006 ◽  
Vol 78 ◽  
pp. S37-S38
Author(s):  
T. Vuong ◽  
T. Ducruet ◽  
N. Kopek ◽  
L. Portelance ◽  
B. Bahoric ◽  
...  
Keyword(s):  
Anal Canal ◽  
Therapeutic Index ◽  
Anal Canal Cancer ◽  
Improve Treatment ◽  
Conformal Therapy

221 Long term follow up results of conformal therapy for patients with anal canal cancer

2005 ◽  
Vol 76 ◽  
pp. S65
Author(s):  
N. Kopek ◽  
T. Vuong ◽  
L. Portelance ◽  
B. Bahoric ◽  
K. Sultanem ◽  
...  
Keyword(s):  
Anal Canal ◽  
Anal Canal Cancer ◽  
Conformal Therapy ◽  
Long Term Follow Up

Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience

2007 ◽  
Vol 25 (29) ◽  
pp. 4581-4586 ◽  
Author(s):  
Joseph K. Salama ◽  
Loren K. Mell ◽  
David A. Schomas ◽  
Robert C. Miller ◽  
Kiran Devisetty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Cancer Patients ◽  
Intensity Modulated Radiation Therapy ◽  
Complete Response ◽  
Concurrent Chemotherapy ◽  
Hiv Positive ◽  
Anal Canal Cancer ◽  
Intensity Modulated ◽  
Dermatologic Toxicity

PurposeTo report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT).Patients and MethodsFrom October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography–based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria.ResultsMedian follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively.ConclusionPreliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

Sign in / Sign up

Export Citation Format

Share Document